NRI.TO - Nuvo Pharmaceuticals Inc.

Toronto - Toronto Delayed Price. Currency in CAD

Nuvo Pharmaceuticals Inc.

7560 Airport Road
Unit 10
Mississauga, ON L4T 4H4

Full Time Employees47

Key Executives

Mr. John C. London LLB, LLMChief Exec. Officer and Director555.62kN/AN/A
Mr. Jesse F. LedgerPres217.36kN/AN/A
Ms. Mary-Jane E. Burkett CPA-CA, HBAChief Financial Officer, VP and Corp. Controller193.63kN/AN/A
Mr. Calogero Lunetta MScVP of Manufacturing338.67kN/AN/A
Dr. Bernard Joseph Chiasson Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Nuvo Pharmaceuticals Inc., a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; and Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

Corporate Governance

Nuvo Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.